01 3Xanax
02 5Xanax/Xanax XR
03 1Xanax/Xanax Xr
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 198
2018 Revenue in Millions : 223
Growth (%) : -11
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 157
2021 Revenue in Millions : 186
Growth (%) : -16
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 155
2022 Revenue in Millions : 157
Growth (%) : -1
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -8.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 253
2014 Revenue in Millions : 224
Growth (%) : -11%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 222
2015 Revenue in Millions : 224
Growth (%) : -1
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 225
2016 Revenue in Millions : 223
Growth (%) : 1
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 222
2017 Revenue in Millions : 225
Growth (%) : -1%
Upjohn (9 months)
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 149
2019 Revenue in Millions : 147
Growth (%) : 1
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
LOOKING FOR A SUPPLIER?